tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Sean Laaman, 2 are a HOLD (28.57%), 5 are a BUY (71.43%).
Analyst Sean Laaman, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 100% that have a potential upside of 12.39% achieved within 60 days.
Sean Laaman’s has documented 13 price targets and ratings displayed on 2 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on RMD, ResMed at 26-Apr-2024.
Analyst best performing recommendations are on RMD (RESMED).
The best stock recommendation documented was for RMD (RESMED) at 6/17/2020. The price target of $176 was fulfilled within 8 days with a profit of $10.36 (6.25%) receiving and performance score of 7.82.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
$330
$51.41 (18.45%)
$285
22 days ago
(18-Sep-2025)
6/7 (85.71%)
$56.71 (20.75%)
42
Buy
$330
$51.41 (18.45%)
$120
22 days ago
(18-Sep-2025)
5/6 (83.33%)
$56.71 (20.75%)
110
Buy
$270
$-8.59 (-3.08%)
$250
2 months 24 days ago
(16-Jul-2025)
12/12 (100%)
$15.75 (6.19%)
106
Hold
$248
$-30.59 (-10.98%)
$260
5 months 16 days ago
(24-Apr-2025)
3/3 (100%)
$11.9 (5.04%)
70
Buy
$290
$11.41 (4.10%)
$286
5 months 16 days ago
(24-Apr-2025)
18/18 (100%)
$53.9 (22.83%)
353
What Year was the first public recommendation made by Sean Laaman?
